A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis
Objective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS).Methods: Twenty-four patients with 5-year RRMS evolution and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-10-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.01046/full |
| _version_ | 1828898439535001600 |
|---|---|
| author | María Inés Herrera María Inés Herrera Rodolfo Alberto Kölliker-Frers Rodolfo Alberto Kölliker-Frers Matilde Otero-Losada Santiago Perez Lloret Macarena Filippo Julia Tau Francisco Capani Francisco Capani Francisco Capani Francisco Capani Andrés M. Villa |
| author_facet | María Inés Herrera María Inés Herrera Rodolfo Alberto Kölliker-Frers Rodolfo Alberto Kölliker-Frers Matilde Otero-Losada Santiago Perez Lloret Macarena Filippo Julia Tau Francisco Capani Francisco Capani Francisco Capani Francisco Capani Andrés M. Villa |
| author_sort | María Inés Herrera |
| collection | DOAJ |
| description | Objective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS).Methods: Twenty-four patients with 5-year RRMS evolution and eleven healthy control subjects entered the study. None of the participants had an inflammatory systemic or metabolic disease. Disability progression was evaluated using the Expanded Disability Status Scale. Serum level of pNF-H, the anti-inflammatory cytokine transforming growth factor-β 1 (TGF-β1), and the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17A (IL-17A), monocyte chemotactic protein-1 (MCP-1), and soluble intercellular cell-adhesion molecule 1 (sICAM-1) were quantified using enzyme-linked immunosorbent assay (ELISA).Results: The patients had higher serum level of TGF-β1, IL-6, sICAM-1, and pNF-H. Based on these findings, a sample of at least 49 controls and 89 recent-onset RRMS patients is required to find an at least 1-point between-group difference in pNF-H with a power of 80% and an α error = 0.05. The progression of the disease was correlated with the level of pNF-H (Spearman rho = 0.624, p = 0.006), but not with the cytokines'.Conclusions: The serum level of pNF-H, EDSS score-correlated, might stand for a potential biomarker of disability in RRMS reflecting progressive axonal damage and cumulative neurological deterioration. The novelty of these results warrants conducting a larger confirmatory trial. |
| first_indexed | 2024-12-13T15:15:44Z |
| format | Article |
| id | doaj.art-c5ba756be00a4592bd863074c275c6c0 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-13T15:15:44Z |
| publishDate | 2019-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-c5ba756be00a4592bd863074c275c6c02022-12-21T23:40:43ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-10-011010.3389/fneur.2019.01046469421A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple SclerosisMaría Inés Herrera0María Inés Herrera1Rodolfo Alberto Kölliker-Frers2Rodolfo Alberto Kölliker-Frers3Matilde Otero-Losada4Santiago Perez Lloret5Macarena Filippo6Julia Tau7Francisco Capani8Francisco Capani9Francisco Capani10Francisco Capani11Andrés M. Villa12Instituto de Investigaciones Cardiológicas, National Research Council, Universidad de Buenos Aires (ININCA, UBA-CONICET), Buenos Aires, ArgentinaCentro de Investigaciones en Psicología y Psicopedagogía, Pontificia Universidad Católica Argentina (CIPP, UCA), Buenos Aires, ArgentinaInstituto de Investigaciones Cardiológicas, National Research Council, Universidad de Buenos Aires (ININCA, UBA-CONICET), Buenos Aires, ArgentinaFacultad de Farmacia y Bioquímica, Universidad Maimónides, Buenos Aires, ArgentinaInstituto de Investigaciones Cardiológicas, National Research Council, Universidad de Buenos Aires (ININCA, UBA-CONICET), Buenos Aires, ArgentinaInstituto de Investigaciones Cardiológicas, National Research Council, Universidad de Buenos Aires (ININCA, UBA-CONICET), Buenos Aires, ArgentinaCentro de Investigaciones en Psicología y Psicopedagogía, Pontificia Universidad Católica Argentina (CIPP, UCA), Buenos Aires, ArgentinaLaboratorio de Investigación Ocular, Departamento de Patología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, ArgentinaInstituto de Investigaciones Cardiológicas, National Research Council, Universidad de Buenos Aires (ININCA, UBA-CONICET), Buenos Aires, ArgentinaDepartamento de Biología, Universidad John F. Kennedy, Buenos Aires, ArgentinaFacultad de Psicología, Pontificia Universidad Católica Argentina UCA, Buenos Aires, ArgentinaInstituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, ChileSeccion de Neuroinmunología Clínica, Servicio de Neurología, Hospital José María Ramos íMejía, Buenos Aires, ArgentinaObjective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS).Methods: Twenty-four patients with 5-year RRMS evolution and eleven healthy control subjects entered the study. None of the participants had an inflammatory systemic or metabolic disease. Disability progression was evaluated using the Expanded Disability Status Scale. Serum level of pNF-H, the anti-inflammatory cytokine transforming growth factor-β 1 (TGF-β1), and the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17A (IL-17A), monocyte chemotactic protein-1 (MCP-1), and soluble intercellular cell-adhesion molecule 1 (sICAM-1) were quantified using enzyme-linked immunosorbent assay (ELISA).Results: The patients had higher serum level of TGF-β1, IL-6, sICAM-1, and pNF-H. Based on these findings, a sample of at least 49 controls and 89 recent-onset RRMS patients is required to find an at least 1-point between-group difference in pNF-H with a power of 80% and an α error = 0.05. The progression of the disease was correlated with the level of pNF-H (Spearman rho = 0.624, p = 0.006), but not with the cytokines'.Conclusions: The serum level of pNF-H, EDSS score-correlated, might stand for a potential biomarker of disability in RRMS reflecting progressive axonal damage and cumulative neurological deterioration. The novelty of these results warrants conducting a larger confirmatory trial.https://www.frontiersin.org/article/10.3389/fneur.2019.01046/fullrelapsing-remitting multiple sclerosisbiomarker potentialneurofilament heavy chain phosphoformcytokinesdisability progressionexpanded disability status scale |
| spellingShingle | María Inés Herrera María Inés Herrera Rodolfo Alberto Kölliker-Frers Rodolfo Alberto Kölliker-Frers Matilde Otero-Losada Santiago Perez Lloret Macarena Filippo Julia Tau Francisco Capani Francisco Capani Francisco Capani Francisco Capani Andrés M. Villa A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis Frontiers in Neurology relapsing-remitting multiple sclerosis biomarker potential neurofilament heavy chain phosphoform cytokines disability progression expanded disability status scale |
| title | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| title_full | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| title_fullStr | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| title_full_unstemmed | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| title_short | A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis |
| title_sort | pilot cross sectional study to investigate the biomarker potential of phosphorylated neurofilament h and immune mediators of disability in patients with 5 year relapsing remitting multiple sclerosis |
| topic | relapsing-remitting multiple sclerosis biomarker potential neurofilament heavy chain phosphoform cytokines disability progression expanded disability status scale |
| url | https://www.frontiersin.org/article/10.3389/fneur.2019.01046/full |
| work_keys_str_mv | AT mariainesherrera apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT mariainesherrera apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT rodolfoalbertokollikerfrers apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT rodolfoalbertokollikerfrers apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT matildeoterolosada apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT santiagoperezlloret apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT macarenafilippo apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT juliatau apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT andresmvilla apilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT mariainesherrera pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT mariainesherrera pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT rodolfoalbertokollikerfrers pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT rodolfoalbertokollikerfrers pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT matildeoterolosada pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT santiagoperezlloret pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT macarenafilippo pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT juliatau pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT franciscocapani pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis AT andresmvilla pilotcrosssectionalstudytoinvestigatethebiomarkerpotentialofphosphorylatedneurofilamenthandimmunemediatorsofdisabilityinpatientswith5yearrelapsingremittingmultiplesclerosis |